A University of British Columbia (“UBC”) spin-off, BirchBioMed holds the exclusive worldwide pharmaceutical license for two medical therapeutic technologies from UBC that mark significant medical breakthroughs in the treatment of fibrosis and certain autoimmune diseases.

Initially funded by key strategic donors and government bodies, including the Canadian Institute of Health Research and the National Science and Engineering Research Counsel (the Canadian counterpart of the U.S. National Institutes of Health), our licensed technology has benefited from more than $6 million in government and association grants, coupled with additional university resources. It is also the first technology that UBC, or any other Canadian institution, has advanced from the discovery stage through to Phase 1 clinical trials with support strictly from government and private donations.

This highly significant achievement — coupled with extensive funding from Canada’s most prestigious government research institutions – are an index of this technology’s potential importance and incalculable impact on society. Its promise resulted in UBC extending it unprecedented advantages, beginning with the vital milestone of completing phase 1 clinical trials.